$RGNT News

Regentis Biomaterials Reports Strong Surgeon Interest in GelrinC(R) at 8th ICRS Summit in Portugal

Regentis Biomaterials to Present at the 2026 ThinkEquity Conference on October 15 in New York City

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Ehud Geller, CEO of Regentis Biomaterials Ltd.

Regentis Biomaterials (RGNT) Advances GelrinC as a Potential New Approach to Knee Cartilage Repair

Regentis Biomaterials Reports First Half 2026 Financial Results and Provides Corporate Update

Regentis Biomaterials H1 EPS $(0.44) Up From $(1.17) YoY

Regenerative Hydrogel Is Redefining Cartilage Repair as Regentis Advances GelrinC

Regentis Biomaterials (RGNT) Moves GelrinC Along Parallel US Clinical and European Commercial Tracks

Regentis Biomaterials (RGNT) Builds a Manufacturing and Intellectual Property Powerhouse for the Global Cartilage Repair Market

Regentis Biomaterials (RGNT) Advances Regenerative Solution for Major Unmet Need in Cartilage Repair

Regentis Biomaterials (RGNT) Targets $3B Cartilage Repair Market with Cell-Free Gelrin C

Regentis Biomaterials (RGNT) Positioned to Benefit as Regenerative Medicine Reshapes the Growing $3B Cartilage Repair Market

Regentis Receives Japanese Patent allowance, Strengthening its Global GelrinC Intellectual Property Portfolio with New Proprietary Manufacturing Technology

Regentis Gets Japan Patent Office Notice of Allowance For Organic Solvent‑Free Protein‑Polymer Conjugate Compositions, Covering GelrinC Manufacturing Process And Ready‑to‑Use Liquid Formulation for Articular Cartilage Repair

Regentis Biomaterials (RGNT) Receives European Approval for Next-Generation GelrinC Manufacturing Process

Regentis Receives European Regulatory Approval for New GelrinC Manufacturing Process, Increasing Production Yield by 400% Ahead of European Commercial Launch

Regentis Biomaterials Receives European Regulatory Approval For New GelrinC Manufacturing Process

Regentis Biomaterials Announces Pricing of a $6.5 Million Private Placement

Why Is Regentis Biomaterials Stock Rising On Wednesday?

Regentis Biomaterials Slips 9% After Soaring 506% On Monday — Here's Why RGNT Stock Is Trending